Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Business
  • Tech
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
Orbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors
  • Press Releases

Orbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors

  • The Pharma Data
  • March 7, 2025

Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address…

Read MoreOrbital Therapeutics Welcomes Biopharma Leader Geno Germano to Board of Directors
Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024
  • Business

Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024

  • The Pharma Data
  • March 7, 2025

Stevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024 Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the…

Read MoreStevanato Group Achieves Record €1.1 Billion Revenue in Fiscal Year 2024
Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy
  • News

Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy

  • The Pharma Data
  • March 7, 2025

Italfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy Italfarmaco S.p.A., a global pharmaceutical company dedicated to developing innovative treatments for rare diseases, has provided a comprehensive update on the regulatory…

Read MoreItalfarmaco Updates on Givinostat for Duchenne Muscular Dystrophy
Leading Cancer Center Adopts Abridge AI for Oncology Documentation
  • Press Releases

Leading Cancer Center Adopts Abridge AI for Oncology Documentation

  • The Pharma Data
  • March 6, 2025

Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering…

Read MoreLeading Cancer Center Adopts Abridge AI for Oncology Documentation
CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target
  • Press Releases

CB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target

  • The Pharma Data
  • March 6, 2025

Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development…

Read MoreCB Capital Gives Estrella Immunopharma (ESLA) Buy Rating, $14 Target
Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp
  • News

Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp

  • The Pharma Data
  • March 6, 2025

Alnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the pioneering leader in RNA interference (RNAi) therapeutics, today announced the retirement…

Read MoreAlnylam Announces Retirement of Co-Founder and Esteemed Board Member Dr. Phillip A. Sharp
Bicycle Therapeutics Announces Inducement Grants
  • Regulatory

Bicycle Therapeutics Announces Inducement Grants

  • The Pharma Data
  • March 6, 2025

Bicycle Therapeutics Announces Inducement Grants Bicycle Therapeutics plc (NASDAQ: BCYC), a pioneering biotechnology company focused on developing a new class of therapeutics known as Bicycle® molecules, announced that on March…

Read MoreBicycle Therapeutics Announces Inducement Grants
LEO Pharma Survey Chronic Hand Eczema Misunderstood and Undermanaged
  • Press Releases

LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged

  • The Pharma Data
  • March 6, 2025

LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged LEO Pharma Survey Highlights Widespread Misunderstanding and Inadequate Management of Chronic Hand Eczema Among Dermatology Providers A recent survey commissioned by…

Read MoreLEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged
Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair
  • News

Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair

  • The Pharma Data
  • March 6, 2025

Orbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair Orbis Medicines, a pioneering leader in oral macrocycle drug discovery, has announced the appointment of Mikael Dolsten, M.D., Ph.D., as…

Read MoreOrbis Medicines Appoints Industry Veteran Mikael Dolsten as Board Chair
FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis
  • Regulatory

FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis

  • The Pharma Data
  • March 6, 2025

FDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced that the U.S. Food and Drug Administration…

Read MoreFDA Accepts sBLA for Genentech’s Gazyva in Lupus Nephritis
  • News

Bionova Launches New Process Development and Pilot Plant in Fremont

  • The Pharma Data
  • March 5, 2025

Bionova Launches New Process Development and Pilot Plant in Fremont Bionova Scientific, an Asahi Kasei company and boutique commercial-scale biologics contract development and manufacturing organization (CDMO), has officially announced the…

Read MoreBionova Launches New Process Development and Pilot Plant in Fremont
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication
  • Press Releases

GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication

  • The Pharma Data
  • March 5, 2025

GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication GeneDx (Nasdaq: WGS), a leading innovator in genomic insights, has announced an expansion of its genetic…

Read MoreGeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication
PrevNext
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Javelin Biotech and Pfizer Report Clinical PK Prediction Findings Using Multi-Tissue Chip Platform
  • HighRes and Waters Partner to Accelerate Drug Discovery with Robotic Automation
  • Merck KGaA and Versant Ventures Launch Saturnus Bio to Advance Rare Genetic Cardiomyopathy Treatments
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.